N-异丙基环己烷甲酰胺 | 6335-52-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-异丙基环己烷甲酰胺
• 英文名称: N-isopropylcyclohexanecarboxamide
• 英文别名: N-propan-2-ylcyclohexanecarboxamide
• CAS: 6335-52-0
• 化学式: C₁₀H₁₉NO
• mdl: MFCD01342402
• 分子量: 169.267
• InChiKey: ABESZBBWDFJISN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-异丙基环己烷甲酰胺 在 2-氟吡啶 、 三氟甲磺酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以78%的产率得到环己甲腈
  参考文献：
  名称：

  脂族和芳族仲酰胺向腈的多功能和化学选择性转化

  摘要：

  三氟甲磺酸酐与2-氟吡啶结合可有效地使仲酰胺脱水，在温和的反应条件下提供腈。该反应是一般性的，并且与带有仲，叔或苄基N-烷基的脂族，α，β-不饱和，芳族和杂芳族酰胺的使用相容。该反应还显示出对仲酰胺的良好的化学选择性至优异的化学选择性，并能耐受几个不稳定的官能团。

  DOI：

  10.1016/j.tet.2015.03.094
• 作为产物：
  描述：

  N,N-diisopropylcyclohexanecarboxamide 在 甲烷磺酸 作用下， 反应 5.0h， 以79%的产率得到N-异丙基环己烷甲酰胺
  参考文献：
  名称：

  酸介导的N-异丙基叔酰胺的脱保护

  摘要：

  通过在甲磺酸中加热，将含有N-异丙基的叔酰胺选择性地脱保护。该Ñ -异丙基团是在酰胺氮上的其它基团，例如甲基，伯烷基或芳基的存在下选择性地除去。当将苯甲醚作为助溶剂加入时，假定的异丙基阳离子会被苯甲醚的Friedel-Crafts烷基化捕获。

  DOI：

  10.1016/j.tetlet.2015.01.161

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF
  申请人：Samumed, LLC

  公开号：US20140194441A1

  公开（公告）日：2014-07-10

  Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  揭示了用于治疗各种疾病和病理的吲唑化合物。更具体地，本公开涉及使用吲唑化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺部疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经系统疾病/疾患/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• Synthesis of Aliphatic Amides through a Photoredox Catalyzed Radical Carbonylation Involving Organosilicates as Alkyl Radical Precursors
  作者：Alex Cartier、Etienne Levernier、Anne‐Lise Dhimane、Takahide Fukuyama、Cyril Ollivier、Ilhyong Ryu、Louis Fensterbank

  DOI：10.1002/adsc.202000314

  日期：2020.5.26

  Alkyl radicals, from primary to tertiary, formed by photocatalyzed oxidation of organosilicates, are involved efficiently in radical carbonylation with carbon monoxide (CO), in the presence of various amines and CCl4, leading to a variety of amides in moderate to good yields.

  在各种胺和CCl 4的存在下，通过有机硅酸盐的光催化氧化形成的伯基到伯基的烷基有效地参与一氧化碳（CO）的自由基羰基化反应，从而以中等至良好的收率生成了各种酰胺。
• Mild and Low-Pressure<i>fac</i>-Ir(ppy)₃-Mediated Radical Aminocarbonylation of Unactivated Alkyl Iodides through Visible-Light Photoredox Catalysis
  作者：Shiao Y. Chow、Marc Y. Stevens、Linda Åkerbladh、Sara Bergman、Luke R. Odell

  DOI：10.1002/chem.201601694

  日期：2016.6.27

  unactivated alkyl iodides employing a fac‐Ir(ppy)3‐catalyzed radical aminocarbonylation protocol has been developed. Using a two‐chambered system, alkyl iodides, fac‐Ir(ppy)3, amines, reductants, and CO gas (released ex situ from Mo(CO)6), were combined and subjected to an initial radical reductive dehalogenation generating alkyl radicals, and a subsequent aminocarbonylation with amines affording a

  已经开发出一种新颖，温和且简便的方法，可以通过未活化的烷基碘使用fac- Ir（ppy）3催化的自由基氨基羰基化方法制备烷基酰胺。使用两腔系统，将烷基碘，fac- Ir（ppy）3，胺，还原剂和CO气体（从Mo（CO）6异位释放）合并，并进行初始自由基还原性脱卤，生成烷基自由基，然后用胺进行氨基羰基化，以中等到极好的收率提供了广泛的烷基酰胺。